People affected by the lethal glioblastoma cancer only live for 12–18 months after diagnosis.
A global trial that began in 2007 has confirmed that a vaccine for the treatment of the most lethal brain cancer can give patients years of extended life.
Peterschreiber.media/iStock.
“This is a potent molecule that’s very exciting to us in terms of its potential for deployment against glioblastoma,” said Steve Kay, Ph.D., the senior author of the study.
Galactica was supposed to help \.
Commentary: The public can access new research faster than ever before. But in the era of misinformation, new challenges emerge.
“A world without heart attack and stroke” — New video from our 2022 #RejuvenationStartupSummit: Mike Kope, CEO of Corporate Affairs, Cyclarity Therapeutics — prevents age-related conditions such as atherosclerosis, heart attack, and stroke by addressing the root cause. Enjoy!
Mike Kope, CEO of Cyclarity Therapeutics at Rejuvenation Startup Summit 2022.
Connect to Forever Healthy:
“Leveraging a platform to develop therapeutics that render calcified tissue and organs supple again” — New video from our #RejuvenationStartupSummit: Matthias Breugelmans, CEO of Elastrin Therapeutics Inc… Enjoy!
Matthias Breugelmans, CEO of Elastrin Therapeutics at Rejuvenation Startup Summit 2022.
Connect to Forever Healthy:
By mushrooms…?
People like Nathan have found out first hand that they can. You may have also seen scientists and doctors talking about mycotherapy for serious chronic conditions like cancer and HIV. That’s because many conditions thought of as diseases really have the same cause– an immune system that was unbalanced and compromised by environmental factors or diet.
Certain foods we eat are inflammatory, they boost problematic cells in our body called TH2 cytokines, which cause inflammation, and these cells can cause allergic reactions, auto-immune conditions, and weaken the cancer-fighting TH1 cytokines. When the TH1 cytokines are weakened by inflammatory foods, cancer is allowed to thrive and grow and spread.
But our bodies naturally have the ability to fight diseases and cancers, that’s what our immune system’ does.
The cells responsible for finding and removing cancer in our body, the TH1 cytokines, do this amazingly– but inflammatory foods and environments shut them down and prevent these natural cells from doing their jobs and killing cancerous cells quickly.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.
This research, published November 17 in BMJ Open Ophthalmology, is the first to identify which types of high-risk cardiovascular and carotid artery disease are linked to the eye disorder. The findings could prompt increased screening to save vision, diagnose undetected heart disease, and prevent adverse cardiovascular events.
“For the first time, we have been able to connect these specific high-risk cardiovascular diseases to a specific form of AMD, the one with subretinal drusenoid deposits (SDDs),” explains lead author R. Theodore Smith, MD, Ph.D., Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai.
Patient-specific modeling could help clinicians determine whether an individual’s brain aneurysm is at risk of bursting.
This is the first time scientists have observed vessels form with such a close resemblance to the complicated structure of naturally occurring blood vessels.
An international research collaboration headed by the University of Sydney has created technology that allows for the production of materials that mirror the structure of living blood vessels, with major implications for the future of surgery.
Preclinical research showed that once the manufactured blood vessel was transplanted into mice, the body accepted it and new cells and tissue began to develop in the appropriate locations, thereby converting it into a “living blood vessel.”
The “most complicated therapy ever” tailors bespoke, genome-edited immune cells to attack tumors.
Scientists at the Garvan Institute of Medical Research have identified molecular profiles of the surrounding matrix of a common type of lung cancer that might indicate which patients are likely to develop aggressive tumors.
Squamous cell carcinoma is the second most prevalent type of lung cancer. Yet treatment options for these patients remain limited and have remained largely unchanged over decades. High rates of recurrence and chemotherapy resistance mean that less than one in five patients will survive more than five years after their diagnosis.
In addition to studying cancer cells, Garvan researchers have been turning their attention to the environment that surrounds these cancer cells in the tumor. A major component of this environment is the extracellular matrix, a 3D meshwork of around 300 core molecules. This matrix is present in all tissues in the body, where it normally provides structural and functional support to hold cells together. But in cancers, this matrix is fundamentally altered and these changes can promote tumor growth.
